Novel drug launches will lift global Alzheimer's disease market $13.7 billion in 2030

8 June 2023

The market for Alzheimer's disease (AD) drugs is projected to experience robust growth at a compound annual growth rate of 20.0% from $2.2 billion in 2020 to $13.7 billion in 2030 across the eight major markets (8MM: the USA, France, German, Spain, the UK, Japan and China).

This expansion is primarily attributed to the introduction of pioneering therapies aimed at addressing the challenges posed by AD, says sector analytics firm GlobalData.

GlobalData’s latest report, “ Alzheimer’s Disease: Eight-Market Drug Forecast and Market Analysis – Update,” reveals that the main driver of growth will be the launch of 23 new pipeline products, including novel symptomatic therapies for the treatment of agitation associated with AD and the entry of disease-modifying therapies (DMTs) to the market.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK